Seroprevalence of cytomegalovirus antibodies amongst normal pregnant women in Nigeria

Akinsegun Abduljaleel
Akinbami1
Kabiru Afolarin Rabiu2
Adeniyi Abiodun Adewunmi2
Kikelomo Ololade Wright3
Adedoyin Owolabi Dosunmu1
Titilope Adenike Adeyemo4
Adewumi Adediran4
Vincent Oluseye Osunkalu4

1Department of Haematology and Blood Transfusion, 2Department of Obstetrics and Gynaecology, 3Department of Community Medicine and Primary Health Care, College of Medicine, Lagos State University, Ikeja, 4Department of Haematology and Blood Transfusion, College of Medicine, Faculty of Clinical Sciences, University of Lagos, Iyara, Nigeria

Objective: Cytomegalovirus (CMV), a ubiquitous virus belonging to the herpes family, is known to be transmitted frequently to developing fetuses in pregnancy. In an immunocompromised state like pregnancy, primary infection through blood transfusion or reactivation of a latent CMV infection can cause severe illness. The study was carried out to determine the seroprevalence of the immunoglobulin G (IgG) antibody to cytomegalovirus amongst pregnant women in correlation with previous exposure to blood transfusion.

Methods: A cross sectional study was carried out amongst 179 HIV negative pregnant women attending the antenatal clinic of Lagos State University Teaching Hospital (LASUTH), Ikeja, Nigeria. Five mL of blood was collected and stored in a plain bottle, centrifuged on the same day and the serum stored at −20°C. All samples were screened for anti-CMV IgG antibodies using the enzyme linked immunosorbent assay (ELISA). Consenting participants were instructed to fill a semi-structured questionnaire to obtain demographic and other related information. Statistical analysis of the results was done using Pearson’s chi squared test for analytical assessment.

Results: A total of 97.2% of the pregnant women recruited for this study were anti-CMV IgG positive. Out of the 179 recruited for the study 174 responded to the question on previous history of blood transfusion, 14.9% of the respondents (26 of 174) had a previous history of blood transfusion and all tested positive to the anti-CMV IgG antibody. However, past history of blood transfusion and educational level were found to be insignificant to the risk of acquiring CMV infection.

Conclusion: The seroprevalence of the CMV antibody amongst pregnant women in this environment is high in relation to findings in other developing countries. There is the need to assess anti-CMV immunoglobulin M antibodies in pregnant women, which is a determinant of active infection.

Keywords: CMV, IgG, pregnant women

Introduction

Cytomegalovirus belongs to the subfamily of herpes known as β herpes and it is found universally in various geographic locations. CMV infection is also known to be frequently transmitted to a developing fetus. This virus remains the leading cause of congenital viral infection and a significant cause of transfusion-acquired infections in patient populations.1 Its clinical manifestations include asymptomatic forms, severe fetal damage, and death in rare cases due to spontaneous abortion.

For most healthy people who acquire CMV infection after birth or through blood transfusion, there are few symptoms and no long term sequelae. Therefore, for the vast majority of individuals, CMV infection is innocuous.2 However, CMV
infection is important in pregnant women because of their immunocompromised state and risk of infection to the fetus whose immune system is not fully developed. Furthermore, 10% to 15% of the children who are asymptomatic at birth may develop late sequelae, especially hearing defects, after a period of months or years.\(^3\)

Once a person becomes infected, the virus remains alive but usually dormant within the individual's body for life. Recurrent disease rarely occurs unless the immune system is compromised. It was reported that the risk of fetal damage is greater if the primary infection occurs during the first trimester of pregnancy.\(^4\) The prevalence of congenital infection ranges from 0.2% to 2.5% in different populations,\(^7\) with groups at greater risk including Black or Asian women, those from a low socioeconomic background, and those that are born prematurely.\(^10\)

The prevalence of congenital infection varies with the prevalence of the infection in the population.\(^14\) The seroprevalence of CMV among women of childbearing age ranges from 35% to 95% in different countries.\(^5,14\) It is more widespread in developing countries and in areas of lower socioeconomic conditions.\(^18\)

The rate of seropositivity of anti-CMV immunoglobulin G(IgG) enzyme linked immunosorbent assay (ELISA) antibodies of pregnant women in Turkey was reported to be 98.5\(^{19}\) and 84% in Spain.\(^20\) These rates are much higher than the typical European rate but similar to the rate obtained amongst Black pregnant women.

An overall rate of 87% of anti-CMV IgG ELISA antibodies in pregnant women was reported in Singapore,\(^21\) 100% in Thailand,\(^21\) and 93% in Iranian women of childbearing age.\(^22\)

Since CMV is transmitted through blood transfusion, the strict use of blood during pregnancy and labor cannot be overemphasized as some of the pregnant women could be CMV negative.

Several studies and data support the transmission of CMV from seropositive blood donors to susceptible recipients in a variety of settings.\(^23,24\) Topin et al\(^25\) provided the first biochemical evidence for transfusion associated CMV infection. The study reported that monocyte latently infected with CMV represent the primary vector for Transfusion Associated-CMV (TA-CMV) which can be largely abrogated by transfusing at risk patients with either seronegative units or blood filtered to remove white blood cells. Lamberson et al\(^26\) also determined that a decreased incidence of transfusion associated with CMV (TA-CMV) infection occurred when only blood products that tested negative for CMV immunoglobulin M (IgM) were used.

Two hypotheses have been investigated as possible mechanisms for CMV transmission by blood. First, since CMV resides in a latent state in the infected host, it has been proposed that all CMV-seropositive blood donors can transmit the latent virus,\(^27,28\) following transfusion. In this case latent virus is reactivated and may cause active CMV infection in the recipient. Latency following a primary infection may be punctuated by periodic reactivation that gives rise to recurrent infections, and in utero transmission may occur during either primary or recurrent infections.\(^29\) Yeager and colleagues published an excellent study of TA-CMV infections in newborns to prove this fact.\(^30\) CMV-specific antibody of the IgM class has been recognized as a marker of active or recent primary infection with the virus. Recent reports have shown a positive correlation between post transfusion CMV infection and the receipt of blood from CMV IgM-positive donors.\(^31\)

Such units of blood may be used for CMV negative pregnant women thus increasing the incidence of CMV in the population with its consequent embryopathy such as sensorineural hearing loss, chorioretinitis, mental retardation and fetal death. CMV embryopathy should be a major concern for public health irrespective of the percentage of babies affected. Therefore, the need to determine the seroprevalence of the CMV antibody in pregnant women cannot be overemphasized. This will underscore the significance of CMV screening in blood units for use in pregnancy and labor. This is necessary to avoid the transmission of CMV infected blood to women who are CMV seronegative.

Subjects and method
Study population
A cross sectional study was carried out using the antenatal clinic of Lagos State University Teaching Hospital (LASUTH), Ikeja, Nigeria. The clinic registers about 150 patients daily and all consenting newly registered pregnant women were recruited for the study between July 1 and August 15, 2008. However, approval was obtained from the institution's research and ethics committee (LASUTH Health Research and Ethics Committee). Participants were instructed to fill out a structured questionnaire including demographic information and previous exposure to blood transfusion. Immunocompromised participants with a history of chronic illness, such as hepatitis, sickle cell disease, renal disorders, gestational diabetes and HIV infection were excluded.
Collection of samples
A blood sample of 5 mL was collected into a sterile, non-anticoagulated bottle from each consenting participant. The sample was centrifuged and the serum separated into a sterile bottle and stored at −20°C.

Cytomegalovirus serology
Sera were tested for IgG CMV using the ELISA test. The CMV-specific IgG antibodies were studied by the commercial Dia.Pro Diagnostic Bioprobe CMV IgG (Milan, Italy) according to the manufacturer’s instructions. All specimens were analyzed using the enzyme immunoassay test. The cutoff of IgG was set at 0.5 World Health Organization (WHO) IU/mL (calibrator 2) by the kit’s manufacturer.

Samples with a concentration ≥0.5 WHO IU/mL were considered positive for CMV IgG, while samples with a concentration below the cut off were considered as negative results. The controls and the calibrators passed the validation check recommended by the manufacturer of the kit.

Statistical analysis
Statistical analysis of results was done using the statistical package for social science (SPSS 16.0, IBM, USA). The Pearson chi squared test and multiple comparisons involving post-hoc analysis such as the Bonferonni correction were used for the analytic assessment and the differences were considered to be statistically significant when the P-value obtained was <0.05.

Results
A total of 179 pregnant women were enrolled into the study. About 50.8% of them were between the ages of 25–30 years and 0.60% were under 18 years (Table 1). Almost all of them (97.20%) had anti-CMV IgG antibodies. The majority of those (89 of 179) who had anti-CMV IgG antibodies were between parity 1 and 4 (Table 2). It was observed that most (70.40%) of the patients had tertiary education, followed by 24.60% with secondary education. Less than 2% had no formal education (Table 3). However, levels of education did not correlate with CMV status (P = 0.14).

The majority (86.03%) of the subjects were married and most of them had anti-CMV IgG antibodies, 11.17% were single and 2.7% were separated. (P = 0.11) (Table 4).

One hundred and seventy four of the participants responded to the question on past history of transfusion while 14.94% of the 174 respondents (26 of 174) had a previous history of blood transfusion and all tested positive to the anti-CMV IgG antibody. Equally, 148 of the 174 (85.05%) subjects had no past history of blood transfusion and 143 of the 148 (96.62%) tested positive to anti-CMV IgG antibodies, but only 5 of 148 (3.37%) tested negative to the IgG CMV P = 0.77 (Table 5). Hence an association cannot be established between transfusion history and anti-CMV IgG positivity.

Multiple comparisons involving post hoc analysis such as the Bonferonni correction were done on level of education/CMV serostatus, marital status/CMV serostatus, parity/CMV serostatus, and age/CMV serostatus. The tests of homogeneity of variances were 0.73, 0.11, 0.78, and 0.74 respectively which were not significant, hence the use of Bonferonni rather than the Tamhane’s T2 post-hoc test. None of the mean differences between the groups compared by the test was significant at 0.05 levels. Post-hoc analysis could not be performed on previous history of blood transfusion and anti-CMV seropositivity because there were fewer than three groups.

Discussion
The 97.20% seropositivity rate of IgG anti-CMV antibodies observed in this study amongst pregnant women is in keep-
ing with several studies. As early as 1973, Krech reported that CMV antibodies are more prevalent in developing countries and areas of lower socioeconomic conditions in comparison to developed countries.\textsuperscript{18}Tookey et al,\textsuperscript{32} in a prospective study amongst pregnant women in London, found a seroprevalence as high as 88.2\% in the first pregnancy of women. Their study was, however, ethnically diverse, with the highest prevalence recorded in Asian women at 88.2\%, 77.2\% in Black women, and the lowest in White women at 45.9\%.

The lowest percentage of 45.9\% derived amongst the White pregnant women population reported by Tookey et al, is similar to the overall rate of anti-CMV IgG ELISA of 55.1\% reported amongst French women,\textsuperscript{33} with 68.3\%,\textsuperscript{34} 30.4\%,\textsuperscript{35} 39\%–94\%\textsuperscript{36} and 56.8\%\textsuperscript{37} in Italy, Ireland, the USA, and Australia respectively.

It is noteworthy in this study that age, parity, marital status, and educational level were not associated with the risk of CMV positivity, because they did not reach significant levels.

Blood transfusion-associated CMV infection has been proven extensively.\textsuperscript{5–24} Akinbami (2009) et al\textsuperscript{38} reported a 96\% IgG anti-CMV and 19.5\% IgM anti-CMV antibodies seroprevalence amongst healthy blood donors in Lagos, Nigeria. This is quite significant because one out of every four units of blood donated is acutely infected by CMV because IgM anti-CMV antibody is a marker of active or recent primary infection with the virus. A pregnancy-related hemorrhage is still a major cause of peripartal morbidity and mortality in developing countries and blood transfusion rates may be high in these countries. In a Nigerian audit of 463 consecutive cesarean sections and blood transfusions within a period of 3 years,\textsuperscript{39} 25.2\% cesarean section cases were transfused.

A total of 67.2\% of cesarean sections of these cases were emergency.\textsuperscript{39} The rate of blood transfusion for the various indications were as follows: malpresentation (excluding breech) 66.7\%; placenta previa 59.1\%; uterine rupture 55.6\%; breech delivery 32\%; obstructed labor 28.2\%; previous baby 25\%; previous cesarean section 17.0\%; severe preeclampsia 11.1\%; fetal distress 10.7\%; and others, 10.3\%. Akinola et al\textsuperscript{40} also reported in a similar study a transfusion rate of 13.6\% amongst cesarean section patients in southwestern Nigeria.

Despite the reported rate of lower seroprevalence of anti-CMV IgG ELISA antibodies amongst higher socioeconomic classes and in developed nations,\textsuperscript{18} lower rates of blood transfusion of 4.9\% and 5.4\% were reported by Dathie et al\textsuperscript{41} and Rouse et al\textsuperscript{42} respectively. In Canada\textsuperscript{43} the overall rate of blood transfusion for postpartum hemorrhage was 0.31\%, and 0.49\%, 0.28\%, 0.23\% for emergency cesarean section, vaginal delivery, and elective cesarean section respectively.

In developing countries, the higher rate of anti-CMV IgG seroprevalence associated with higher requirements for blood in pregnant women poses a grave risk of CMV embryopathy. There is the need to assess anti-CMV IgM antibodies in pregnant women in these countries which is a marker of acute infection and more directly related to CMV embryopathy.

Previous history of blood transfusion and socioeconomic status were, however, found in this study not to be significant factors to CMV antibody positivity. This might be related to the high seroprevalence of anti-CMV IgG in the Nigerian population. Future studies in populations with similarly high seroprevalence may need higher recruitment numbers.

Table 4 Marital status with CMV seropositivity

| Marital status | anti-CMV IgG +ve | anti-CMV IgG –ve |
|---------------|-----------------|-----------------|
| Single        | 18              | 2               |
| Married       | 151             | 3               |
| Separated     | 5               | 0               |

Note: \( P = 0.11. \)

Abbreviations: CMV, cytomegalovirus; IgG, immunoglobulin G.

Table 5 Relationship between blood transfusion and anti-CMV IgG seropositivity

| Past transfusion history | anti-CMV IgG +ve | anti-CMV IgG –ve |
|--------------------------|-----------------|-----------------|
| Yes                      | 26              | 0               |
| No                       | 143             | 5               |

Note: \( P = 0.77. \)

Abbreviations: CMV, cytomegalovirus; IgG, immunoglobulin G.

Conclusion

The seroprevalence of anti-CMV IgG is very high amongst pregnant women in Nigeria. Based on previous studies that showed a decrease in the incidence of CMV disease when blood was screened for CMV (IgM), the incidence of the disease can be decreased in Lagos if blood is screened for CMV. Previous blood transfusion exposure was insignificant in the risk of transmission.

Limitations of this study

1. Reliability of information on blood transfusion provided by patients and the possible reasons for finding small numbers of those who have been previously transfused.
2. The use of IgG ELISA assay rather than IgG and IgM in determining seroprevalence of CMV in pregnant women.

Acknowledgments
The authors wish to acknowledge the resident doctors in the Haematology and Obstetrics/Gynaecology departments of Lagos State University Teaching Hospital who assisted greatly in the administration of questionnaires and collection of samples.

Disclosure
The authors report no conflicts of interest in this work.

References
1. Forbes BA. Acquisition of Cytomegalovirus infections: an update. Clin Microbiol Rev. 1989;2(2):204–216.
2. Onarato IM, Morens DM, Martone WJ, Stansfield SK. Epidemiology of Cytomegaloviral infections; recommendations for prevention and control. Rev Infect Dis. 1985;7:479–497.
3. Stagno S, Whitey RJ. Herpes virus infections of pregnancy – part I: cytomegalovirus and Epstein-Barr virus infections. N Engl J Med. 1985;313(20):1270–1274.
4. Stagno S, Pass RF, Cloud G, et al. Primary cytomegalovirus infection in pregnancy. Incidence, transmission to fetus, and clinical outcome. JAMA. 1986;256(14):1904–1908.
5. Logan S, Tookey P, Peckham C. Antenatal and newborn screening for cytomegalovirus. Report of the working party, National Screening Committee (NSC), London, UK, Sep 2000.
6. Adler SP, Marshall B. Cytomegalovirus infections. Pediatr Rev. 2007;28(3):92–100.
7. Demmler GJ. Infectious Diseases Society of America and Centers for Disease Control: summary of a workshop on surveillance for congenital cytomegalovirus disease. Rev Infect Dis. 1991;13(2):315–329.
8. Nelson CT, Demmler GJ. Cytomegalovirus infection in the pregnant mother, fetus, and newborn infant. Clin Perinatol. 1997;24(1):151–160.
9. Gaytman MA, Steegers EAP, Semmekrot BA, Merkus MW, Galama MD. Congenital cytomegalovirus infection: review of the epidemiology and outcome. Obstet Gynecol Surv. 2002;57(4):245–256.
10. Dollard SC, Grosse SD, Ross DS. New estimates of the prevalence of recent infection. Rev Med Virol. 2007;17(5):355–363.
11. Natali A, Valcavi P, Medici MC, Dieci E, Montali S. Cytomegalovirus infection in an Italian population: antibody prevalence, virus excretion and maternal transmission. New Microbiol. 1997;20(2):123–133.
12. Barbi M, Binda S, Caroppi S, et al. Multicity Italian study of congenital cytomegalovirus infection. Pediatr Infect Dis J. 2006;25(2):156–159.
13. Barbi M, Binda S, Primache V, Clerici D. Congenital cytomegalovirus infection in a northern Italian region. Eur J Epidemiol. 1998;14(8):791–796.
14. Malm G, Engman ML. Congenital cytomegalovirus infections. Semin Fetal Neonatal Med. 2007;12(3):154–159.
15. Colugnati FAB, Staras SAS, Dollard SC, Cannon MJ. Incidence of cytomegalovirus infection among the general population and pregnant women in the United States. BMC Infect Dis. 2007;7:article 71.
16. Staras SAS, Dollard SC, Radford KW, Flanders WD, Pass RF, Cannon MJ. Seroprevalence of cytomegalovirus infection in the United States, 1988–1994. Clin Infect Dis. 2006;43(9):1143–1151.
17. Gambartoto K, Ranger-Rogez S, Aubard Y, et al. Primary cytomegalovirus infection and pregnant women: epidemiological study on 1100 women at Limoges. Pathol Biol. 1997;45(6):453–461.
18. Kretch Y. Complement fixing antibodies against CMV in different parts of the world. Bull World Health Organization. 1973;49:103–106.
19. Ali S, Askin G, Hakan O, et al. CMV seroconversion in pregnancy and the incidence of congenital CMV infection. Turk J Pediatr. 2007;49:30–36.
20. Estrapeant D, Moreno Y, Ahumada R, et al. Seroprevalence of Cytomegalovirus infection in peuperal women and its impact on their newborns. Ann Pediatr. 2007;66:135–139.
21. Wang A, Tunk H, Tee CS, et al. Seroprevalence of Cytomegalovirus, Toxoplasmosis, and Parvovirus in pregnancy. Singapore Med J. 2000;41(4):151–155.
22. Arabou M, Kariyancee K, Jankhah A, et al. Human cytomegalovirus in women of child bearing age throughout Fars province-Iran: A population based cohort study. Malaysian Journal of Microbiology. 2007;3(2):23–28.
23. Chou S. Acquisition of donor strains of CMV by renal transplant recipients. N Engl J Med. 1986;314:1418–1423.
24. Bayer WL, Tegtmeier GE. The blood donor and magnitude of CMV carrier status and the prevalence of CMV antibody. Yale J Biol Med. 1976;49:5–12.
25. Topin MD, Stewart JA, Warren D, et al. Transfusion transmission of CMV confirmed by restriction endonuclease analysis. J Pediatr. 1985;107:953–956.
26. Lamberson HV, McMillan JA, Weiner LB, et al. Prevention of transfusion associated CMV infection in neonates. J Infect Dis. 1988;157:820–827.
27. Norman DJ, Barry JM, Durr M, Wetzsteon PA. Preliminary analysis of a randomized study ofuffy coat transfusions in renal transplantation. Transplant Proc. 1985;17:2330–2332.
28. Opelz G, Terasaki PI. Dominant effect of transfusions on kidney graft survival. Transplantation. 1980;29:153–158.
29. Boppana SB, Rivera B, Fowler KB, et al. Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity. New Engl J Med. 2001;344(18):1366–1371.
30. Yeager AS, Grunet FC, Hafleigh EB, et al. Prevention of transfusion-acquired cytomegalovirus infections in newborn infants. J Pediatr. 1981;98:281–287.
31. Griffiths PD, Stagno S, Pass RF, Smith RJ, Alford CA. Infection with cytomegalovirus during pregnancy: specific IgM antibodies as a marker of recent infection. J Infect Dis. 1982;145:647–653.
32. Tookey PA, Ades AE, Peckham CS. Cytomegalovirus prevalence in pregnant women: the influence of parity. Arch Dis Child. 1992;67(7):779–783.
33. Gratacap-Cavallier B, Bosson JL, Morand P, et al. Cytomegalovirus seroprevalence in French pregnant women: parity and place of birth as major predictive factors. Eur J Epidemiol. 1998;14(2):147–152.
34. Massimo De P, Carlo A, Maria T, Alessia P, Pierangalo C. Low cytomegaloviral infections; recommendations for prevention and control. J Clin Microbiol. 1985;17:2330–2332.
35. Knowles SJ, Grundy KC, Cafferkey MT, et al. Prevention of transfusion-associated cytomegalovirus infection in neonates. Transplantation. 1980;29:153–158.
36. Tookey PA, Ades AE, Peckham CS. Cytomegalovirus prevalence in pregnant women: the influence of parity. Arch Dis Child. 1992;67(7):779–783.
37. Munro SC, Hall B, Whybin LR, et al. Cytomegalovirus antibodies detected by microimmunoassay in newborns. Ann Pediatr. 2007;66:135–139.
38. Akinbami AA, Akanmu AS, Adeyemo TA, et al. Seroprevalence of Cytomegalovirus in Nigerian women of childbearing age. Pediatr Infect Dis J. 2006;25(2):156–159.
39. Colugnati FAB, Staras SAS, Dollard SC, Cannon MJ. Incidence of cytomegalovirus infection among the general population and pregnant women in the United States. BMC Infect Dis. 2007;7:article 71.
40. Staras SAS, Dollard SC, Radford KW, Flanders WD, Pass RF, Cannon MJ. Seroprevalence of cytomegalovirus infection in the United States, 1988–1994. Clin Infect Dis. 2006;43(9):1143–1151.
40. Akinola OI, Fabanwo AO, Tayo AO, et al. Evaluation of blood reservation and use for caesarian sections in a tertiary maternity unit in south western Nigeria. *BMC Pregnancy Childbirth*. 2010;10:57.

41. Dathie SJ, Ghosh A, Ng A, et al. Intra-operative blood loss during elective lower segment caesarian section. *Br J Obstet Gynaecol*. 1992;99:364–367.

42. Rouse DJ, MacPherson C, Landom M, et al. Blood transfusion and caesarian delivery. *Br J Anaesth*. 1998;80:195–198.

43. Balki M, Dhamme S, Kasodeker S et al. Blood transfusion for primary postpartum haemorrhage in a tertiary care hospital. *J Obstet Gynaecol Can*. 2008;30(11):1002–1007.